Mol Cancer 19, 51 (2020)
https://doi.org/10.1186/s12943-020-01174-w
Following publication of the original article [1], the authors identified an error in Fig. 8. In the version of this article initially published, they found one panel in Fig. 8d was used by mistake. The authors want to update it to the correct one. The other elements of the figure remain the same, and the interpretation of the results remains unchanged. The authors’ subsequent studies on MIR22HG have confirmed that the results and conclusions in this study are correct and not affected by this erratum. The correct figure is given below.
MIR22HG increases the CD8 T cells in CRC. a, Scatter plots showing the correlation between CD8A expression and MIR22HG expression. b, Cell-surface expression of PD-L1 and CD8A with overexpressing MIR22HG. Left panels for human cell line and right panels for mouse. c, Relative expression of Cd8a in mice treated with aPD-L1. The right panels showing the IHC staining of CD8A and SMAD2 in tumor and normal tissues of CRC. d, Left panel showing the relative expression of Cd8a in IgG/aPD-L1 + MIR22HG treated mice. Right panel showing the IHC staining of Cd8a. e, The mechanistic scheme of lncRNA MIR22HG in CRC
References
Xu J, Shao T, Song M, et al. MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol Cancer. 2020;19:51. https://doi.org/10.1186/s12943-020-01174-w.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12943-020-01174-w.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Xu, J., Shao, T., Song, M. et al. Correction: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Mol Cancer 22, 116 (2023). https://doi.org/10.1186/s12943-023-01821-y
Published:
DOI: https://doi.org/10.1186/s12943-023-01821-y